A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. - Wikidata - awgldk - TriplyDB

A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder.

A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder.

http://www.wikidata.org/entity/Q37246370

about

Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents Amphetamine, past and present--a pharmacological and clinical perspective Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: a meta-analysis of randomized, controlled trials.Update on optimal use of lisdexamfetamine in the treatment of ADHD.Update on the management of attention-deficit/hyperactivity disorder in children and adults: patient considerations and the role of lisdexamfetamine.A systematic review of the safety of lisdexamfetamine dimesylate.Lisdexamfetamine dimesylate (vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorder Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design.Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder.Focus on Lisdexamfetamine: A Review of its use in Child and Adolescent Psychiatry.Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study.Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day.Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder.Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis ADHD treatments, sleep, and sleep problems: complex associations Phase synchronization of oxygenation waves in the frontal areas of children with attention-deficit hyperactivity disorder detected by optical diffusion spectroscopy correlates with medication.Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults.Efficacy and safety of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder and recent methylphenidate use.NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study.Management of ADHD in children across Europe: patient demographics, physician characteristics and treatment patterns.A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder.Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study.Analysis of individual items on the attention-deficit/hyperactivity disorder symptom rating scale in children and adults: the effects of age and sex in pivotal trials of lisdexamfetamine dimesylate.Lisdexamfetamine in the treatment of adolescents and children with attention-deficit/hyperactivity disorder.Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial.Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting.The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension.Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD.Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.Pharmacological management of narcolepsy and cataplexy in pediatric patients.Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe.Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.

P2860

Q22241419-95894E26-C480-4482-9967-7C20AA4906F1 Q22241826-9D152CCD-9CF5-4D37-9CDC-B95BA051BE52 Q24186168-C1C886EB-A51B-40CC-B4D0-58952A94A452 Q26750486-5D5D61A0-0E9D-4AD3-A92E-412C99B6A9A9 Q26822392-EC18CCB2-BC4F-4139-BFE6-C21E53F1C241 Q27692676-586D892F-9AC1-4A09-BBA0-C9ED6B00334E Q30418053-D03519FF-3631-4BA2-B31A-65F6822843CC Q33571016-193D9924-E08C-4A58-B3E2-19E498330298 Q33755396-03278993-295A-44C2-85B9-8EA4ED74BD23 Q33865315-09606764-60DB-4D7C-9CF8-0DC3A246F980 Q34011677-36FF472C-D28D-4F6D-B7BA-D22F39FE1376 Q34032634-16966641-40FC-4725-A902-73CCD19739B0 Q34232286-B17F975D-7720-4DE8-ACDE-A595D6551074 Q34286130-7CA710A4-52F4-40BB-9F8B-2413B87E1385 Q34421050-E679EB0A-0A35-450E-A377-851A7AAD882F Q34459431-D3DEC3FB-1203-489C-AD8B-1B2F0653F39D Q34498667-65BC11E0-3E18-460F-A918-2EFAB37DCBCE Q34580471-FBBF1608-DF40-483B-986F-0EBA417B05A3 Q34832003-8DEAFF15-5012-4FEA-9F7A-384184412DEC Q35576553-9BD9CFB7-5F04-4A85-96CC-D2C847466E51 Q36233163-3E2CA479-FB90-42B4-8E23-78DF5968E423 Q36457529-CE60FFAE-DD74-41C8-A9E3-EBB28F4E16B7 Q36618017-EDF6725E-859D-4152-A086-783015764FF1 Q36923591-B8F7777F-78E9-4D77-A854-0267281B48CF Q36968227-EE7C966E-D8C6-4A1F-B895-2846F8839E54 Q36983284-89F95286-E986-4F3B-8C85-9100F54B84AF Q37115696-3480E9DD-F853-4A23-96C8-1125AE5B63BC Q37199815-8A92E48D-A253-4189-802D-B2251A41778A Q37320520-DA337D71-6799-4319-A37C-7DEE5A900331 Q37330660-D9258121-CBDD-432C-AD6E-1072A4832957 Q37391143-A64E6AF4-9966-4756-8850-AC40964B8D92 Q37561623-0E47B8EC-EA25-4EF5-A0BF-0B721D5E2464 Q37568899-398AE489-3D32-4B5E-87D3-B30426F8414C Q37667633-85E1248B-76A7-4797-AF16-F9E44F9EC598 Q37791311-8E6FEF45-98D0-41CC-944F-9AC4D392447A Q37803420-EA1FE4ED-380D-46AA-8FA6-A9B7CAF3D73F Q38204833-5118E467-46AC-4F6F-A571-30AD429A01A7 Q38235204-DF8D9757-2E28-4816-AD79-011935DA5311 Q38374695-39A399A6-F8D1-4DE1-AC26-71D1E45B7813 Q38376209-A8934C96-DB6B-4321-B6F9-031D29F75D5A

P2860

A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder.

http://www.wikidata.org/entity/Q37246370

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 June 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A 13-hour laboratory school st ...... eficit/hyperactivity disorder.

@en

A 13-hour laboratory school st ...... eficit/hyperactivity disorder.

@nl

type

label

A 13-hour laboratory school st ...... eficit/hyperactivity disorder.

@en

A 13-hour laboratory school st ...... eficit/hyperactivity disorder.

@nl

prefLabel

A 13-hour laboratory school st ...... eficit/hyperactivity disorder.

@en

A 13-hour laboratory school st ...... eficit/hyperactivity disorder.

@nl

P1433

Q37246370-FACB3AA1-3F96-484C-B253-0CBC1B3DB820

P1476

Q37246370-86CB8398-6A0B-4E18-BAE9-C01217A8C108

P2093

Q37246370-5B3F931B-7D0B-4836-B934-77E9371D5B98

Q37246370-6EF4E335-4C9E-47C9-8011-3BAA94008FD4

Q37246370-807315AF-A6B0-402E-B100-217B5FD7A91A

Q37246370-9D8066B6-6FAC-45EC-860F-9831323EF111

Q37246370-CF10B7B7-BEED-4D2C-8519-86985CA9D2FD

P2860

Q37246370-0244D442-80D9-4048-8B4E-CAD43300D348

Q37246370-1422C555-2058-4FEF-B41C-B37B82EE13E9

Q37246370-37A2BB5C-BC13-48CA-8106-C9F1AC0816B5

Q37246370-39F89DD2-0422-466B-9EDD-EA62BE389728

Q37246370-3E672E9F-BC0E-4382-A37B-87652D7D3B85

Q37246370-45D667DD-F39A-453C-9A65-FF6110283C5B

Q37246370-46FAA6BE-E387-47A5-8189-2346179C4AB8

Q37246370-6EA5179D-3000-4CB3-87D9-43D7D2C06156

Q37246370-76EAC56E-6D4F-45E3-89CF-D9892501EA0A

Q37246370-77DD20F2-6A92-43FE-BA32-55E471E01E74

P2888

Q37246370-4B7E9380-6B4F-492A-A387-547F61ABFD1E

P304

Q37246370-D8DF3531-A9D3-4056-9A0E-DC91951141D6

P31

Q37246370-648B792C-D911-4C85-B32F-2B063B084A71

P356

Q37246370-D0C592C4-F31D-4A01-9421-63EBEE92789A

P433

Q37246370-CE098E89-44D9-4366-BD95-7C955842B797

P478

Q37246370-24EF96DE-9155-43ED-94DE-5CFCB6986649

P577

Q37246370-930BDE97-77A6-4433-90F0-E8BA130CE554

P5875

Q37246370-9BFC410B-1E99-455C-9FD2-4819BDB0B70D

P6179

Q37246370-B4DE84DB-7F4F-441B-A963-E00A7508646C

P698

Q37246370-613AF6F1-C784-4EC8-A741-842BCACB251A

P921

Q37246370-75C5AAD0-3A60-47BE-AA7F-9DB83C79DF1E

Q37246370-D8DCA603-8CDA-4B24-8B2F-B0BED7481CF4

P932

Q37246370-98ED52AC-1088-4528-80B3-3D134910C868

P356

P1433

Child and Adolescent Psychiatry and Mental Health

P1476

A 13-hour laboratory school st ...... eficit/hyperactivity disorder.

@en

P2093

311 Study Group

http://www.w3.org/2001/XMLSchema#string

Ann C Childress

http://www.w3.org/2001/XMLSchema#string

Liza Squires

http://www.w3.org/2001/XMLSchema#string

Scott H Kollins

http://www.w3.org/2001/XMLSchema#string

Sharon B Wigal

http://www.w3.org/2001/XMLSchema#string

P2860

Methyiphenidate vs. amphetamine: Comparative review

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.

The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder.

Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study.

Comparison of the effects of chlorpromazine, dextroamphetamine and methylphenidate on the behaviour and intellectual functioning of hyperactive children

A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD.

Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry.

Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology.

Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.

P2888

P304

17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1753-2000-3-17

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26278309

http://www.w3.org/2001/XMLSchema#string

P6179

1020415147

http://www.w3.org/2001/XMLSchema#string

P698

19508731

http://www.w3.org/2001/XMLSchema#string

P921

attention deficit hyperactivity disorder

P932

2704174

http://www.w3.org/2001/XMLSchema#string